Anti-Thymocyte Globulin interactions
Checked as Antithymocyte immunoglobulin (rabbit) in this data source.
Full monograph for Anti-Thymocyte GlobulinCheck it against another medicine
Medicines
38 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Adalimumabmatched approximately | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Baricitinibmatched approximately | Major | Others | Coadministration of baricitinib with other immunosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. Serious… | 3 sources — open the full entry |
| Clozapinematched approximately | Major | Synergy | Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. | 4 sources — open the full entry |
| Deferipronematched approximately | Major | Synergy | Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity… | 5 sources — open the full entry |
| Deucravacitinibmatched approximately | Major | Synergy | Coadministration of deucravacitinib with other immunosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. | 1 sources — open the full entry |
| Etanerceptmatched approximately | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Golimumabmatched approximately | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Infliximabmatched approximately | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Leflunomidematched approximately | Major | Synergy | The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to… | 2 sources — open the full entry |
| Rotavirus Vaccinematched approximately | Major | Others | The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of… | 9 sources — open the full entry |
| Tofacitinibmatched approximately | Major | Others | Coadministration of tofacitinib with other immunosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. Serious… | 1 sources — open the full entry |
| Upadacitinibmatched approximately | Major | Others | Coadministration of upadacitinib with other immunosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. Serious… | 1 sources — open the full entry |
| Yellow Fever Vaccinematched approximately | Major | Others | The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of…2 documented mechanisms | 19 sources — open the full entry |
| Azathioprinematched approximately | Moderate | Synergy | The use of azathioprine with other immunosuppressive or myelosuppressive agents may result in additive hematologic toxicities and increased risk of infections… | 3 sources — open the full entry |
| Denosumabmatched approximately | Moderate | Synergy | Concomitant use of immunosuppressive or myelosuppressive agents with denosumab may increase the risk of serious infections. Denosumab binds to and inhibits the… | 2 sources — open the full entry |
| Diphtheria + Tetanus + Pertussis + Hepatitis B + Polio + HIBmatched approximately | Moderate | Antagonism | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a… | 10 sources — open the full entry |
| Diroximel Fumaratematched approximately | Moderate | Synergy | The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may… | 1 sources — open the full entry |
| Hepatitis B Vaccine [rDNA]matched approximately | Moderate | Antagonism | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a… | 10 sources — open the full entry |
| Inactivated Hepatitis A vaccinematched approximately | Moderate | Antagonism | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a… | 10 sources — open the full entry |
| Lactobacillus Rhamnosus GGmatched approximately | Moderate | Others | Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms… | 11 sources — open the full entry |
| Ocrelizumabmatched approximately | Moderate | Synergy | The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of… | 1 sources — open the full entry |
| Roflumilast (Tablet)matched approximately | Moderate | Synergy | The concomitant use of roflumilast with immunosuppressive agents has not been adequately studied. Specifically, roflumilast and its active metabolite… | 5 sources — open the full entry |
| Typhoid conjugate vaccinematched approximately | Moderate | Antagonism | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a… | 10 sources — open the full entry |
| Typhoid polysaccharide vaccinematched approximately | Moderate | Others | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a… | 11 sources — open the full entry |
| Beta carotene + Vitamin C + Vitamin Ematched approximately | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Carbonyl Iron + Folic Acid + Zinc Sulfatematched approximately | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Carbonyl Iron + Folic Acid + Zinc Sulfate + Vitamin B Complex + Vitamin Cmatched approximately | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Diphenhydramine Hydrochloride + Zinc Acetatematched approximately | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Ferrous Ascorbate + Folic Acid + Zinc Sulfatematched approximately | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Ferrous Sulfate + Folic Acid + Zinc Sulfatematched approximately | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Glycerin + Hypromellose + Polyethylene glycol + Tetrahydrozoline + Zinc Sulfatematched approximately | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Iron + Folic Acid + Vitamin B Complex + Vitamine C + Zinc Sulfatematched approximately | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Iron Polymaltose Complex + Folic Acid + Zinc Sulfatematched approximately | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Naphazoline + Zinc Sulfatematched approximately | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Tea tree oil + Echinacea + Geothermal watermatched approximately | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Tea Tree Oil + Geothermal Water + Vitamin Ematched approximately | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Vitamin C + Vitamin Ematched approximately | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Vitamin C + Vitamin E + Lutein + Copper + Zincmatched approximately | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
Conditions
Conditions in which Anti-Thymocyte Globulin needs care, as documented in this source.
Infections
MajorThe use of anti-thymocyte globulin [rabbit] is contraindicated in patients who have active acute or chronic infections that contraindicate any additional immunosuppression. To prevent over-immunosuppression, physicians may wish to decrease the dose of the maintenance immunosuppression regimen during the period of therapy use. Low counts of platelets and white blood cells (including low counts of lymphocytes and neutrophils) have been identified and are reversible following dose adjustments. It is recommended to monitor patients carefully and administer appropriate anti-infective treatment when indicated. Also, total white blood cell and platelet counts should be monitored.
1 source
- "Product Information. Thymoglobulin (rabbit) (anti-thymocyte globulin (rabbit))." Genzyme Corporation